Oral 4.03. Needs assessment and design of the first thymic malignancy and myasthenia gravis program

Background Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission, and approximately 15% of patients with MG develop thymic malignancies (TM), most often thymoma. Patients with MG range from healthy outpatients requiring little intervention to those requiring intensive-care level hospitalization. Similarly, there is a wide range of care required for TM patients, with surgical resection performed in most, and more advanced cases also requiring chemotherapy and/or radiotherapy. Although MG and TM are highly linked, to our knowledge, there have been no multidisciplinary programs developed to provide coordinated care for these medically complex patients. This study was performed to define the needs of MG and TM patients and, in doing so, design the first high-quality, efficient multidisciplinary program.